Company Profile

Aciont Inc
Profile last edited on: 2/27/20      CAGE: 4UCB0      UEI:

Business Identifier: Back-of-the-eye therapeutics for sight threatening diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

615 Arapeen Drive Suite #302B
Salt Lake City, UT 84108
   (801) 895-4089
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

Aciont® Inc. is a specialty biopharmaceutical company focused on commercializing localized, non-invasive, controlled and sustained release back-of-the-eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. The underpinning technology platform incorporates a novel sustained release methodology for water soluble or poorly soluble drugs (commonly susceptible to ocular clearance effects) as part of a non-invasive or topical drug delivery system. The company's Visulex technology employs a passive diffusion-based sustained release system that has demonstrated superior pharmacokinetic profiles over other technologies that deliver water soluble and poorly soluble agents passively and actively (iontophoresis) to the posterior pole of the eye; Visulex has been shown to treat retinal disease under a known preclinical model using a variety of proprietary pharmaceutical formulations and methods. Many of the leading back of the eye drug delivery technologies are invasive in nature because they target the eye’s interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops). Aciont's goal is to provide a non-invasive alternative to these drug delivery technologie

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $4,338,839
Project Title: Non-Invasive Drug Delivery to Treat Posterior Uveitis
2010 1 NIH $214,000
Project Title: Novel Method For The Ocular Iontophoretic Delivery Of Avastin And Lucentis
2002 1 NIH $159,509
Project Title: Non-Invasive Blood Phenylalanine Monitor
2002 1 NIH $140,992
Project Title: Improved non-invasive blood glucose monitoring device

Key People / Management

  John W Higuchi -- President and CEO

  Dalynn Berglund

  Balbir Brar -- Vice President, Research and Development

  Charlotte Butler -- Project Manager/Research Scientist

  Abdel-Halim Ghanem

  William I Higuchi -- Chairman of the Board and CTO

  David J Miller

  Donald Mix -- Research Scientist

  Kongnara Papangkorn -- Research Director

Company News

There are no news available.